Genetic background of carcinogenesis in the thyroid gland

Neuroendocrinology Letters

Volumn 28, Issue 2, 2007, Pages 77-105

  Lewiński, Andrzej ^a   Wojciechowska, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Carcinogenesis; Cyclins D1 and E; DNA methylations; LOH; Point mutations; Protooncogenes; Sporadic and hereditary cancers; Structural aberrations; Suppressor genes; Thyroid gland

Indexed keywords

B RAF KINASE; CYCLIN D1; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN RET; RAS PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; THYROTROPIN RECEPTOR;

CANCER GENETICS; CANCER INVASION; CANCER RESEARCH; CARCINOGENESIS; CHROMOSOME 3; CHROMOSOME ARM; DNA METHYLATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HEREDITY; HETEROZYGOSITY LOSS; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; NONHUMAN; PROTO ONCOGENE; REVIEW; THYROID CANCER; THYROID FOLLICLE CELL; THYROID MEDULLARY CARCINOMA; THYROID TUMOR;

EID: 34248578373     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (193)

1. Adams RL, Hanley A, Rinaldi A. DNA demethylation in erythroleukaemia cells. FEBS Lett. 1990; 269: 29-31.
2. Arai T, Yamashita T, Urano T, Masunaga A, Itoyama S, Itoh K, Shiku H, Sugawara I. Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid. Mod Pathol. 1995; 8: 252-256.
3. Aretz S, Stienen D, Uhlhaas S, Loff S, Back W, Pagenstecher C, McLeod DR, Graham GE, Mangold E, Santer R, Propping P, Friedl W. High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat. 2005; 26: 513-519.
4. Ashworth LK, Batzer MA, Brandriff B, Branscomb E, de Jong P, Garcia E, Garnes JA, Gordon LA, Lamerdin JE, Lennon G, Mohrenweiser H, Olsen AS, Slezak T, Carrano AV. An integrated metric physical map of human chromosome 19 Nat Genet. 1995; 11: 422-427.
5. Auguste L-J, Masood S, Westerband A, Belluco C, Valdermma E, Attie J. Oncogene expresion in follicular neoplasms of the thyroid. Am J Surg. 1992; 164: 592-598.
6. Baloh RH, Tansey MG, Johnson EM Jr, Milbrandt J. Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists. J Biol Chem. 2000; 275: 3412-3420.
7. Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhausl W, Vierhapper H. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab. 2005; 90: 6232-6236.
8. Belge G, Rouge L, Soares J, Bruckmann S, Thode B, Fonseca E,, Clode A, Bartnitzke S, Castedo S, Bullerdiek J. Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology. Cancer Genet Cytogenet. 1998; 101: 42-48.
9. Bevan S, Pal T, Greenberg CR, Green H, Wixey J, Bignell G, Narod SA, Foulkes WD, Stratton MR, Houlston RS. A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1.J Clin Endocrinol Metab. 2001; 86: 3701-3704.
10. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P, Sun S, Stoffer SS, Goldgar DE, Romeo G, Houlston RS, Narod SA, Startton MR, Foulkes WD. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997; 61: 1123-1130.
11. Bollag G, Freeman S, Lyons JF, Post LE. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs. 2003; 4: 1436-1441.
12. Boltze C, Zack S, Quednow C, Bettge S, Roessner A, Schneider-Stock R. Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathol Res Pract. 2003; 199: 399-404.
13. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D., In vitro reconstruction of tumour initiation in a human epithelium. Oncogene. 1994; 9: 281-290
14. Bourasseau I, Savagner F, Rodien P, Duquenne M, Reynier P, Guyetant S, Bigorgne JC, Malthiery Y, Rohmer V No evidence of thyrotropin receptor and G(s alpha) gene mutation in high iodine uptake thyroid carcinoma Thyroid. 2000; 10: 761-765.
15. Broaddus RR, Lynch PM, Lu KH, Luthra R, Michelson SJ. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol. 2004; 17: 981-989.
16. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene. 2000; 19: 3146-3155.
17. Brzeziańska E, Karbownik M, Migdalska-Sek M, Pastuszak-Lewandoska D, Włoch J, Lewiński A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in Polish population. Mutat Res. 2006; 599: 26-35.
18. Brzeziańska E, Migdalska-Sek M, Pastuszak-Lewandoska D, Wojciechowska K, Lewiński A. Incidence assessment of BRAF V599E mutation in papillary thyroid carcinoma in Polish population. (Abstract P-02-15). Endokrynol Pol - Polish J Endocrinol. 2005; 56: 560-561.
19. Brzeziańska E, Pastuszak-Lewandoska D, Cyniak-Magierska A, Lewiński A. Molecular analysis of loss of heterozygosity (LOH) at 3p24.3 locus (c-erAβ gene) in papillary thyroid carcinoma. (Abstract). Endokrynol Pol - Polish J Endocrinol. 2005; 56: 370.
20. Brzeziańska E, Pastuszak-Lewandoska D, Cyniak-Magierska A, Lewiński A. Ocena ekspresji cykliny D1 w nowotworach tarczycy jako marker inwazyjności nowotworu [(Estimation of cyclin D1 expression in thyroid neoplasms as a neoplasmatic invasive marker) (In Polish)]. Endokrynol Pol - Polish J Endocrinol. 2006; 57(suppl. A): 106.
21. Bulow C, Bulow S. Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Int J Colorectal Dis. 1997; 12: 240-242.
22. Cabrera JR, Sanchez-Pulido L, Rojas AM, Valencia A, Manes S, Naranjo JR, Mellstrom B. GAS1 is related to the GDNF family receptors alpha and regulates ret signaling. J Biol Chem. 2006; 281: 14330-14339.
23. Canzian F, Amati P, Harach R. A gene predisposing to familial thyroid tumors with oxyphilia maps to chromosome 19p13.2. Am J Hum Genet.1998; 63: 1743-1748.
24. Caudill CM, Zhu Z, Ciampi R, Stringer JR, Nikiforov YE Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab. 2005; 90: 2364-2369.
25. Cetta F, Pelizzo MR, Curia MC, Barbarisi A. Genetic and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. Am J Pathol. 1999; 155: 7-9.
26. Cheng A-J, Lin J-D, Chang T, Wang T-CV. Telomerase activity in benign and malignant human thyroid tissues. Br J Cancer. 1998; 77: 2177-2180.
27. Chen R-X, Masuda T, Fujimori K, Naganuma H, Takaya K, Mori Y, Nagura H. High-risk group of differentiated thyroid carcinoma with p53 overexpression and local recurrence. Thyroidology Clin Exp. 1998; 10: 125-130.
28. Chen ST, Shieh HY, Lin JD, Chang KS, Lin KH. Overexpression of thyroid hormone receptor beta1 is associated with thyrotropin receptor gene expression and proliferation in a human thyroid carcinoma cell line. J Endocrinol. 2000; 165: 379-389.
29. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005; 115: 94-101.
30. Clurman BE, Groudine M. The CDKN2 tumor-suppressor locus- a tale of two proteins. N Engl J Med.1998; 338: 910-912.
31. Cobb MH. MAP kinase signaling pathways. Promega Notes Magazine 1996; 56: 37-42.
32. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH. Mutational analysis of BRAF in fine needle aspiration biopsies of thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Can Res. 2004; 10: 2761-2765.
33. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Can Inst. 2003; 95: 625-627.
34. Costa P, Domingues R, Sobrinho LG, Bugalho MJ. RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population. Endocrine. 2005; 27: 239-243.
35. Cyniak-Magierska A, Brzeziańska E, Pastuszak-Lewandoska D, Januszkiewicz J, Lewiński A. Analiza wystepowania mutacji punktowych w onkogenach z rodziny RAS w raku brodawkowatym gruczołu tarczowego [Analysis of the prevalence of family RAS oncogenes point mutations in papillary thyroid carcinoma (in Polish)]. Abstract, Endokrynol Pol - Pol J Endocrinol. 2004; 55: 98-99.
36. Cyniak-Magierska A, Brzeziańska E, Pastuszak-Lewandoska D, Migdalska-Sek M, Lewiński A. Ocena ekspresji onkogenu c-MET w raku brodawkowatym gruczołu tarczowego [Analysis of c-MET oncogene expression in papillary thyroid carcinoma (In Polish)]. Abstract, Endokrynol Pol - Pol J Endocrinol. 2004; 55: 109.
37. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res. 2001; 61: 3105-3109.
38. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954.
39. Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev. 1995; 16: 259-270.
40. Derwahl M. Editorial: TSH receptor and Gsa gene mutations in the pathogenesis of toxic thyroid adenomas - a note of caution. J Clin Endocrinol Metab. 1996; 81: 2783-2785.
41. Di Cristofaro J, Vasko V, Savchenko V, Cherenko S, Larin A, Ringel MD, Saji M, Marcy M, Henry JF, Carayon P, De Micco C. ret/PTC1 and ret/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patients. Endocr Relat Cancer. 2005; 12: 173-183.
42. Digel W, Lubbert W. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results Crit Rev Oncol Hematol. 2005; 55: 1-11.
43. Di Renzo MF, Olivero M, Ferro S, Prat M, Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R, Pierotti MA, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene. 1992; 7: 2549-2553.
44. Domingues R, Mendonca E, Sobrinho L, Bugalho MJ. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology. 2005; 16: 27-31.
45. Dvorakova S, Vaclavikova E, Sykorova V, Duskova J, Vlcek P, Ryska A, Novak Z, Bendlova B. New Multiple Somatic Mutations in the RET Proto-oncogene Associated with a Sporadic Medullary Thyroid Carcinoma. Thyroid. 2006; 16: 311-316.
46. Elgadi A, Frisk T, Larsson C, Wallin G, Hoog A, Zedenius J, Norgren S. Lack of mutations in the TSHr and Gsalpha genes in TSHr antibody negative Graves' disease. Exp Clin Endocrinol Diabetes. 2005; 113: 516-521.
47. Fagin JA. Genetic basis of endocrine disease 3. Molecular defects in thyroid gland neoplasia. J Clin Endocrinol Metab. 1992; 75: 1398-1400.
48. Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, Gonsky R. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res. 1996; 56: 765-771.
49. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr Rev. 1994; 15: 202-232.
50. Ferenc T, Lewiński A. Udział czynników genetycznych w patogenezie nowotworów tarczycy wywodzacych sie z komórki pecherzykowej tego gruczołu [Participation of genetic factors in the pathogenesis of thyroid neoplasms derived from the follicular cell of this gland (In Polish]. Endokrynol Pol - Polish J Endocrinol. 1999; 50 (suppl. 1 to no. 4): 61-90
51. Ferenc T, Lewinski A, Lange D, Niewiadomska H, Sygut J, Sporny S, Jarzab B, Salacinska-Los E, Kulig A, Wloch J. Analysis of P161NK4A protein expression in follicular thyroid tumors. Pol J Pathol. 2004; 55: 143-148.
52. Ferenc T, Lewinski A, Lange D, Niewiadomska H, Sygut J, Sporny S, Jarzab B, Salacinska-Los E, Kulig A, Wloch J. Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors. Pol J Pathol. 2005; 56: 27-35.
53. Ferenc T, Lewiński A, Pastuszak-Lewandoska D. Rak rdzeniasty tarczycy - zagadnienia genetyczne i badania przesiewowe [Medullary thyroid carcinoma - genetic problems and screening tests (In Polish)]. Endokrynol Pol - Polish J Endocrinol. 1997; 48 (suppl. 2 to no. 2): 177-188.
54. Fernandez RM, Navarro E, Antinolo G, Ruiz-Ferrer M, Borrego S. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients. Int J Mol Med. 2006; 17: 575-581.
55. Figge J, Bakst G, Weisheit D, Solis O, Ross JS. Image analysis quantitation of immunoreactive retinoblastoma protein in human thyroid neoplasms with a streptavidin-biotin- peroxidase staining technique. Am J Pathol. 1991; 139: 1213-1219.
56. Forster-Gibson CJ, Mulligan LM. Multiple endocrine neoplasia type 2. Eur J Cancer. 1994; 13: 1969-1974.
57. Francis-Lang H, Zannini M, De Felice M, Berligieri MT, Fusco A, Di Lauro L. Multiple mechanism of interference between transformation and differentation in thyroid cells. Mol Cel Biol. 1992; 12: 5793-5880.
58. Frattini M, Ferrarion C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Piarotti MA, Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004; 23: 7436-7440.
59. Frilling A, Happner W, Eng C, Mulligan LM, Raue F, Broelsch CE. Presymptomatic genetic screening in families with multiple endocrine neoplasia type 22. J Mol Med. 1995; 73: 229-233.
60. Fugazzola L, Mannavol D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol. 2004; 61: 239-243.
61. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003; 22: 6455-6457.
62. Furmaniak J, Smith BR. Immunity to the thyroid-stimulating hormone receptor. Springer Semin Immunopathol. 1993; 3: 143-146.
63. Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 1998; 58: 5002-5008.
64. Fusco L, Viglietto G, Santoro M. A new mechanism of BRAF activation in human thyroid papillary carcinomas. J. Clin. Invest. 2005; 115: 20-23.
65. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 2001; 158: 987-996.
66. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005; 65: 10199-10207.
67. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov JE. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005; 24: 6646-6656.
68. Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer. 1997; 19: 112-123.
69. Greenblatt MS, Benett WP, Holstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54: 4855-4878.
70. Herrmann ME, Talpos GB, Mohamed AN, Saxe A, Ratner S, Lalley PA, Wolman SR. Genetic markers in thyroid tumors. Surgery. 1991; 110: 941-948.
71. Hiasa Y, Konishi N, Tao M, Matsuda H, Tsumatani K, Nakamura Y, Kitahori Y, Ozono S, Hirao Y, Okajima E. Different expression of nm23-H1 and nm23-H2 protein with proliferative activities in various sizes of human renal cell carcinoma. Oncology. 1996; 53: 79-87.
72. Houlston RS, Stratton MR. Genetics of non-medullary thyroid cancer. Quart J Med. 1995; 88: 685-693.
73. Hubner RA, Houlston RS Molecular advances in medullary thyroid cancer diagnostics. Clin Chim Acta. 2006; 370: 2-8.
74. Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A. S100A4 expression is an early event of papillary carcinoma of the thyroid. Oncology. 2004; 67: 397-402.
75. Janota-Bzowski M, Czarnocka B, McIntosh RS, Asghar MS, Watson PF, Kemp H, Pastuszko D, Łyczkowska A, Carayon P, Weetman AP. Comparison of immunodominant regions of TPO defined by murine anti-human TPO monoclonal antibodies and recombinant anti-TPO IgGK Fab fragments from patients with Hashimoto's thyroiditis. Endokrynol Pol - Polish J Endocrinol 1997; 48: 237-247.
76. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C, Denis MG. Real-time allele-specific amplification for sensitive detection of BRAF mutation V600E. Mol Cell Probes.2004; 18: 349-352.
77. Jones C, Shaw JJ, Wyllie FS, Gaillard N, Schlumberger M, Wynford-Thomas D. High frequency deletion of the tumour suppressor gene p16INK4a (MTS1) in human thyroid cancer cell lines. Mol Cell Endocrinol. 1996; 116: 115-119.
78. Kameyama K, Mukai M, Takami H, Ito K. Cribriform-morular variant of papillary thyroid carcinoma: ultrastructural study and somatic/germline mutation analysis of the APC gene. Ultrastruct Pathol. 2004; 28: 97-102.
79. Karga H, Lee J-K, Vickery AL, Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991; 73: 832-836.
80. Karges B, Krause G, Homoki J, Debatin KM, de Roux N, Karges W. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5 J Endocrinol. 2005; 186: 377-385.
81. Kato Y, Ying H, Willingham MC, Cheng SY. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis. Endocrinology. 2004; 145: 4430-4438.
82. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA; Nikiforov YE; Fagin J A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 36: 1454-1457.
83. Kimura ET, Vanvooren V, van Sande J, Nikiforov YE, Fagin JA. Autonomously functioning thyroid nodules are not associated with BRAF mutations. Clin Endocrinol. 2004; 60: 394-396.
84. King SK, Southwell BR, Hutson JM. An association of multiple endocrine neoplasia 2B, a RET mutation; constipation; and low substance P - nerve fiber density in colonic circular muscle. J Pediatr Surg. 2006; 41: 437-442.
85. Krohn K, Paschke R. BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules. Thyroid. 2004; 14: 359-361.
86. Kohrle J. Guard your master: thyroid hormone receptors protect their gland of origin from thyroid cancer. Endocrinology. 2004; 145: 4427-4429.
87. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005; 15: 531-544.
88. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science. 2000; 289: 1357-1360.
89. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S, Hemminki K. BRAF mutations in metastatic melanoma; a possible association with clinical outcome. Clin Cancer Res. 2003; 9: 3362-3368.
90. La Perle KM, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol. 2000; 157: 671-677.
91. Lee S, Hong SW, Shin SJ, Kim YM, Rhee Y, Jeon BI, Moon WC, Oh MR, Lim SK. Papillary thyroid carcinoma associated with familial adenomatous polyposis: molecular analysis of pathogenesis in a family and review of the literature. Endocr J. 2004; 51: 317-323.
92. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs. 2003; 4: 757-763.
93. Lemoine NR, Mayall ES, Stringer B, Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 1989; 4: 159-164.
94. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED, Wynford-Thomas D. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988; 48: 4459-4463.
95. Leprat F, Bonichon F, Guyot M, Trouette H, Trojani M, Vergnot V, Longy M, Belleannee G, de Mascarel A, Roger P. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families. Clin Endocrinol. 1999; 50: 589-594.
96. Lewiński A. Postepy w endokrynologii [Advances in endocrinology (In Polish)]. Med. Prakt. 2003; 1-2: 90-100.
97. Lewiński A, Ferenc T. Karcinogenéza v śtítnej žl'aze - ǔčast' genetickŷch factorov. In: Kreza A, Langer P, Klimeś I, Stárka L, Payer J, Michalek J. Všeobecná a klinická Endokrinólogia [Carcinogenesis in the thyroid gland - participation of genetic factors. In: General and Clinical Endocrinology (In Slovak)], Academic Electronic Press, Bratislava; 2004. p. 285-297.
98. Lewiński A, Ferenc T, Sporny S, Jarzab B. Thyroid carcinoma: diagnostic and therapeutic approach; genetic background (review). Endocrine Regul. 2000; 34: 99-113.
99. Lewiński A, Gesing A. Czynniki wzrostowe gruczołu tarczowego i ich udział w patogenezie raka tarczycy [Thyroid growth factors and their involvement in the pathogenesis of thyroid carcinoma (In Polish)]. Endokrynol Pol - Polish J Endocrinol.1995; 46 (suppl. 2 to no. 3): 11-27.
100. Lewiński A, Marcinkowska M, Brzeziańska E, Tantush AS, Włoch J, Brzeziński J. Effect of Exogenous Insulin-like Growth Factor-I (IGF-I) on the Expression of the IGF-I Gene and the Genes of IGF-Binding Proteins (IGFBPs) 1-4 in human thyroid cells from nodular goiter, follicular adenoma and follicular carcinoma cultured in monolayers. J Endocr Genet. 2003; 3: 141-149.
101. Lewiński A, Marcinkowska M, Brzeziańska E, Włoch J, Brzeziński J. Expression of insulin-like growth factor I (IGF-I) gene and of genes for IGF-binding proteins 1, 2, 3, 4 (IGFBP-I-IGFBP-4) in non-neoplastic human thyroid cells and in certain human thyroid cancers. Effect of exogenous IGF-I on this expression. Endocr Res. 2004; 30: 47-59.
102. Lewiński A, Pawlikowski M, Cardinali D. Thyroid growth-stimulating and growth-inhibiting factors. A review. Biol Signals.1993; 2: 313-351.
103. Limon J, Mitelman F. Znaczenie aberracji chromosomowych w litych guzach nowotworowych człowieka [The significance of chromosomal aberrations in solid neoplastic tumors in humans (In Polish)]. Pat Pol. 1994, 45: 1-15
104. Liu RT, Hou CY, You HL, Huang CC, Hock-Liew, Chou FF, Wang PW, Cheng JT. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid. 2004; 14: 616-621.
105. Liu Y, Jiang C, Tan Y. [Pathological study on the expression of cell adhesion molecules and metastasis suppressor gene in thyroid follicular carcinoma and papillary carcinoma] (In Chinese)]. Zhonghua Bing Li Xue Za Zhi. 2002; 31: 322-326.
106. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, Comoglio PM, Di Renzo MF. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion Cancer Res. 2002; 62: 7025-7030.
107. Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Malchoff DM. Familial papillary thyroid carcinoma is genetically distinct from familial adenomatous polyposis coli. Thyroid. 1999; 9: 247-252.
108. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer. 1994; 30A: 987-993.
109. Martinez R, Venturelli D, Perrotti D, Veronese ML, Kastury K, Druck T, Huebner K, Calabretta B. Gene structure, promoter activity, and chromosomal location of the DR-nm23 gene, a related member of the nm23 gene family. Cancer Res. 1997; 57: 1180-1187.
110. Matsuo K, Tang SH, Fagin JA. Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. Mol Endocrinol. 1991; 38: 1-14.
111. Matsuo K, Tang SH, Zeki K, Gutman RA, Fagin JA. Aberrant deoxyribonucleic acid methylation in human thyroid tumors. J Clin Endocrinol Metab. 1993; 77: 991-995.
112. Miyake N, Maeta H, Horie S, Kitamura Y, Nanba E, Kobayashi K, Terada T. Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathol Int. 2001; 51: 680-685.
113. McDermott MT. Oncogenes and thyroid cancer. In: Falk SA, editor. Thyroid disease: Endocrinology, Surgery, Nuclear Medicine, and Radiotherapy. Philadelphia: Lippicott-Raven Publishers; 1997. p. 231-239.
114. McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J, Hoffman L, Burgess J, Duffield A, Papotti M, Stark M, Sobol H, Maes B, Murat A, Kaariainen H, Bertholon-Gregoire M, Zini M, Rossing MA, Toubert ME, Bonichon F, Cavarec M, Bernard AM, Boneu A, Leprat F, Haas O, Lasset C, Schlumberger M, Canzian F, Goldgar DE, Romeo G. Localization of a susceptibility gene for familial non-medullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 2001; 69: 440-446.
115. McKay JD, Williamson J, Lesueur F, Stark M, Duffield A, Canzian F, Romeo G, Hoffman L. At least three genes account for familial papillary thyroid carcinoma: TCO and MNG1 excluded as susceptibility loci from a large Tasmanian family. Eur J Endocrinol. 1999; 141: 122-125.
116. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochem Biophys Acta. 2003; 1653: 25-40.
117. Michelin S, Daya-Grosjean L, Sureau F, Said S, Sarasin A, Suarez HG. Characterization of a c-met proto-oncogene activated in human xeroderma pigmentosum cells after treatment with N-methyl-N′-nitro-N-nitrosoguanidine (MNNG). Oncogene. 1993; 8: 1983-1991.
118. Monaco C, Califano D, Chiappetta G, et al. Mutated human Kirsten ras, driven by a thyroglobulin promoter, induces a growth advantage and partially dedifferentiates rat thyroid epithelial cells in vitro. Int J Cancer. 1995; 63: 757-760.
119. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene. 1997; 14: 729-740.
120. Motokura T, Arnold A. Cyclins and oncogenesis. Biochim Biophys Acta. 1993; 1155: 63-78.
121. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson SN, Lehnert H, Heumann HPH, Thibodeau SN, Ponder BAJ. Specific mutation of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet. 1994; 6: 70-74.
122. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, Gagel RF, Takai S-I, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C. Genotype-fenotype correlation in multiple endocrine neoplasia type 2: report of the international RET mutation consortium. J Intern Med. 1995; 228: 343-346.
123. Mulligan LM, Ponder BAJ. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 1995; 80: 1989-1995.
124. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, Qian X, Sebo TJ, Erickson LA, Lloyd RV. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 2005; 85: 1065-1075.
125. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab. 1990; 71: 223-229.
126. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TL, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003; 88: 4393-4397.
127. Nemec J, Soumar J, Zamrazil V, Pohunkova D, Motlik K, Mirejowski P. Familial occurrence of differentiated (non-medullary) thyroid cancer. Oncology. 1975; 32: 151-157.
128. Neumann S, Willgerodt H, Ackermann F, Reske A, Jung M, Reis A, Paschke R. Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I- symporter. J Clin Endocrinol Metab. 1999; 84: 3750-3756.
129. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol. 2004; 15: 319-327.
130. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munos H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57: 1690-1694.
131. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 2004; 209: 1-6.
132. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov JE. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88: 5399-5404.
133. Oler G, Ebina KN, Kimura ET, Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol. 2005; 4: 509-511.
134. Paschke R. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Exp Clin Endocrinol Diabet. 1996; 104 (suppl 4): 129-132.
135. Pickett CA, Agoff SN, Widman TJ, Bronner MP. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid. 2005; 15: 461-473.
136. Pierotti MA, Bongarzone I, Borrello MG, Greco A, Pilotti S, Sozzi G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chrom Cancer. 1996; 16: 1-14.
137. Ponder BAJ. Genetic screening for multiple endocrine neoplasia type 2. Exp Clin Endocrinol. 1993; 101: 53-56.
138. Portella G, Vitagliano D, Borselli C, Melillo RM, Salvatore D, Rothstein JL, Vecchio G, Fusco A, Santoro M. Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res. 1999; 11: 421-427.
139. Powell Jr DJ, Russell JP, Li G, Kuo BA, Fidanza V, Huebner K, Rothstein JL. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice Oncogene. 2001; 20: 3235-3246.
140. Pujol RM, Matias-Guiu X, Miralles J, Colomer A, de Moragas JM. Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity? J Am Acad Dermatol. 1997; 37(2 Pt 2): 349-352.
141. Puskas LG, Juhasz F, Zarva A, Hackler L Jr, Farid NR. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol (Noisy-le-grand). 2005; 51: 177-186.
142. Puxendu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni
143. Puzianowska-Kuźnicka M, Madej A, Krystyniak A, Stachlewska-Nasfeter E, Nauman A, Nauman J. Trijodotyronina i jej receptory jadrowe w procesie nowotworzenia [Triiodothyronine and its nuclear receptor in the process of neoplasia (In Polish)]. Post Biol Kom. 2002; 28: 183-196.
144. Quesnel B, Fenaux P, Philippe N, Founier J, Bonneterre J, Preudhomme C, Peyrat JP. Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer. 1995; 72: 351-353.
145. Quiros RM, Ding HG, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005; 11: 2261-2268.
146. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V, Martuciello G. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med. 1998; 243: 515-520.
147. Rouge L, Castedo S, Gomes P, Soares P, Clode A, Soares J. Cytogenetic findings in 18 follicular thyroid adenomas. Cancer Genet Cytogenet. 1993; 67: 1-6.
148. Saitoh K, Takahashi H, Yamamoto M, Kishi H, Parsons PG. Expression of metastasis suppressor gene product, nm23 protein, is not inversely correlated with the tumour progression in human malignant melanomas. Histopathology. 1996; 29: 497-505.
149. Sakai Y, Koizumi K, Sugitani I, Nakagawa K, Arai M, Utsunomiya J, Muto T, Fujita R, Kato Y. Familial adenomatous polyposis associated with multiple endocrine neoplasia type 1-related tumors and thyroid carcinoma: a case report with clinicopathologic and molecular analyses. Am J Surg Pathol. 2002; 26: 103-110.
150. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22: 2954-2963.
151. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Damman R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002; 62: 3698-3701.
152. Schnabel P, Böhm M. Mutations of signal-transducing G proteins in human disease. J Mol Med.1995; 73: 221-228.
153. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997; 57: 3126-3130.
154. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 1999; 5: 810-816.
155. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, Lushnikov E, Kumagai T, Nakashima M, Meirmanov S, Mine M, Hayashi T, Yamashita S. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol. 2004; 6: 1729-1735.
156. Shi YF, Zou MJ, Schmidt H, Juhasz F, Stensky V, Robb D, Farid NR. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res. 1991; 51: 2690-2693.
157. Soares P, Cameselle-Teijeiro J, Sobrinho-Simoes M. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology. 1994; 24: 205-210.
158. Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, Fonseca E, de Castro IV, Cameselle-Teijeiro J, Cardoso-Oliveira M, Sabrincho-Simoes M. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 2004; 6: 572-576.
159. Soares P, Trovisco V, Rocha AS, Limo J, Castro P, Preto A, Maximo F, Botelho T, Seruco R, Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in etiopathogenesis of PTC. Oncogene. 2003; 17: 4578-4580.
160. Soravia C, Sugg SL, Berk T, Mitri A, Cheng H, Gallinger S, Cohen Z, Asa SL, Bapat BV. Familial adenomatous polyposis-associated thyroid cancer - a clinical, pathological, and molecular genetics study. Am J Pathol. 1999; 154: 127-135.
161. Suarez HG. Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol. 1998; 48: 531-546.
162. Suarez HG, Du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Permentier C, Monier R. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene. 1990; 5: 565-570.
163. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the ret protooncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 1988; 3: 571-578.
164. Taruscio D, Carcangiu ML, Ried T, Ward DC. Numerical chromosomal aberrations in thyroid tumors detected by double fluorescence in situ hybridization. Genes Chrom Cancer 1994; 9: 180-185.
165. Tennis M, Krishnan S, Bonner M, Ambrosone CB, Vena JE, Moysich K, Swede H, McCann S, Hall P, Shields PG, Freudenheim JL. p53 mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol Biomarkers Prev. 2006; 15: 80-85.
166. Teyssier JR, Liautaud-Roger F, Ferre D, Patey M, Dufer J. Chromosomal changes in thyroid tumors. Relation with DNA content, karyotypic features, and clinical data. Cancer Genet Cytogenet. 1990; 50: 249-263.
167. Tsilchorozidou T, Vafiadou E, Yovos JG, Romeo G, McKay J, Lesueur F, Bonora E. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci. Thyroid. 2005; 15: 1349-1354.
168. Tomoda C, Miyauchi A, Uruno T, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Kuma S, Kuma K, Kakudo K. Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg. 2004; 28: 886-889.
169. Trovisco V, de Castro IV, Soares P, Maximo V, Silva P, Magalhães J, Abrosimov A, Guiu XM, Sobrinho-Simoes M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004; 202: 247-251.
170. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moireira S, Meireles AM, Mgalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 2005; 446: 589-595.
171. Trovisco V, Soares P, Soares R, Mgalhaes J, Sa-Couto P, Sobrinho-Simoes M. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol. 2005; 36: 694-697.
172. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 2001; 439: 725-751.
173. Vasko V, Hu Sh, Wu G, Xing JC, Larin A, Savchenko V, Trink B, Xing M. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab. 2005; 90: 5265-5269.
174. Vdovichenko KK, Markova SI, Belokhvostov AS. Mutant form of BRAF gene in blood plasma of cancer patients. Ann N Y Acad Sci. 2004; 1022: 228-231.
175. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Bartford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell.2004; 6: 855-867.
176. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol. 2005; 29: 544-549.
177. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells J Cell Biol. 1993; 121: 145-154.
178. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell.1995; 81: 323-330.
179. Wiench M, Wloch J, Oczko M, Gubala E, Jarzab B. Rearrangement of RET gene in papillary thyroid carcinoma [Article in Polish] Wiad Lek. 2001; 54 (Suppl 1): 64-71.
180. Wozniak A, Wiench M, Olejniczak A, Wloch J, Lachinski A, Lange D, Olczyk T, Jarzab B, Limon J. Loss of heterozygosity in 73 human thyroid tumors. Neuroendocrinol Lett. 2005; 26: 521-525.
181. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002; 161: 1549-1556.
182. Wyllie FS, Lemoine NR, Wiliams ED, Wynford-Thomas D. Structure and expression of nuclear oncogenes in multi-stage thyroid tumorgenesis. Br J Cancer. 1989; 60: 592-598.
183. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004; 64: 1664-1668.
184. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D, Ladenson PW. Detection of BRAF mutation of fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 2004; 89: 2867-2872.
185. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab. 2004; 89: 1365-1368.
186. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003; 63: 4561-4567.
187. Xu B, Yoshimoto K, Miyauchi A, Kuma S, Mizusawa N, Hirokawa M, Sano T. Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. J Pathol. 2003; 199: 58-67.
188. Yamamoto M, Hoshino H, Onizuka T, Ichikawa M, Kawakubo A, Hayakawa S. Thyroid papillary adenocarcinoma in a women with Peutz-Jeghers syndrome. Intern Med. 1992, 31: 1117-1119
189. Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY. Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res. 2003; 63: 5274-5280.
190. Zafon C, Obiols G, Castellvi J, Tallada N, Galofre P, Gemar E, Mesa J, Simo R. nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001; 86: 3975-3980.
191. Zou M, Al-Baradie RS, Al-Hindi H, Farid NR, Shi Y. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer. 2005; 93: 1277-1284.
192. Zou M, Famulski KS, Parhar RS, Baitei E, Al-Mohanna FA, Farid NR, Shi Y. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab. 2004; 89: 6146-6154.
193. Zou M, Shi Y, al-Sedairy S, Farid NR. High levels of Nm23 gene expression in advanced stage of thyroid carcinomas. Br J Cancer. 1993; 68: 385-388.